Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake [Yahoo! Finance]
Biogen Inc. (BIIB)
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
biogen.com/en_us/investors.html
Company Research
Source: Yahoo! Finance
Earnings rose 8% year over year, driven by savings in operating costs and margin improvements. On a constant-currency basis, earnings were flat. Total revenues came in at $2.29 billion, down 7% on both reported basis and constant-currency basis from the year-ago quarter due to lower sales of key multiple sclerosis (MS) drugs like Tecfidera and Tysabri as well as spinal muscular atrophy (SMA) drug, Spinraza. Sales missed the Zacks Consensus Estimate of $2.32 billion. Product sales in the quarter were $1.71 billion, down 3% year over year. Revenues from anti-CD20 therapeutic programs declined 1% to $394.0 million. The revenues include royalties on sales of Roche's Ocrevus and Biogen's share of Roche's drugs, Rituxan, Gazyva and Lunsumio. Contract manufacturing and royalty revenues declined 39% in the quarter to $184.6 million. Contract manufacturing and royalty revenues include Biogen's 50% share of revenues (including royalties) from the Leqembi collaboration with Eisai and reven
Show less
Read more
Impact Snapshot
Event Time:
BIIB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIIB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
News
- Biogen Inc. (NASDAQ: BIIB) had its price target raised by analysts at HSBC Holdings plc from $339.00 to $342.00. They now have a "buy" rating on the stock.MarketBeat
- Biogen Reports Progress on Corporate Responsibility Priorities [Yahoo! Finance]Yahoo! Finance
- Biogen Reports Progress on Corporate Responsibility PrioritiesGlobeNewswire
- Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]Yahoo! Finance
- Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings [Seeking Alpha]Seeking Alpha
BIIB
Earnings
- 4/25/24 - Beat
BIIB
Sec Filings
- 5/3/24 - Form 4
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- BIIB's page on the SEC website